It is perhaps extraordinary how many treatment modalities for patients with AML are considered standard care without data that support such a premise. In some instances there are at least major question marks around a particular concept or therapy that is administered. Such observations apply to induction therapy, post remission-therapy, therapy of secondary leukemias and bone marrow transplantation.
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The gold standard for induction therapy in AML, in most parts of the world, is the combination with which most new or different induction regimens are compared; that is, a standard 3+7 regimen, which consists of daunorubicin 45 mg/m 2 for 3 days together with cytarabine 100 mg/m 2 by continuous infusion for 7 days. The choice of anthracycline has actually been studied extensively in well-conducted prospective randomized studies. Yet, strangely enough, very few data support the choice of daunorubicin at this dose in preference to other agents. In fact, the opposite is true. In patients younger than 55-60 years, multiple prospective randomized studies have compared daunorubicin 45 mg/m 2 with idarubicin, amsacrine, mitroxantrone or aclacinomycin A, while keeping the dose of cytarabine constant. Virtually all of these agents proved superior to daunorubicin 45-50 mg/m 2 . In this age group, four randomized clinical trials, that included over 800 patients, compared idarubicin at a dose of 12-13 mg/m 2 with daunorubicin 45 mg/m 2 while maintaining the same dose of cytarabine. [1] [2] [3] [4] Each of these studies demonstrated a superior response rate for idarubicin in younger adults. Furthermore, a meta-analysis of these studies conducted by the AML Collaborative Group in Great Britain 5 confirmed that the complete response rate associated with idarubicin after only one cycle of therapy was significantly higher than that associated with daunorubicin. Similar trials using amsacrine, 6 mitoxantrone 7 or aclacinomycin A 8 all showed either a statistically significant improvement, or at least a very strong trend, in favor of an alternate anthracycline or anthraquinone when compared with daunorubicin 45-50 mg/m 2 . Thus, virtually any anthracycline or anthraquinone that has been compared with daunorubicin at a dose of 45 mg/m 2 in adult patients with AML who are less than 55-60 years has been found to be superior. It remains unclear why daunorubicin at this dose remains the standard of care in many parts of the world.
These data, however, do not establish the superiority of any of the other anthracyclines or anthraquinones over daunorubicin; it is not clear whether the comparative advantages result from an inherent biologic superiority or from comparison to a specific dosage of daunorubicin. It is possible, even likely, that the studies compared non-equivalent doses. No prospec- 9,10 and from ECOG, 11, 12 suggest that higher doses of daunorubicin may yield higher complete response rates. Although these are not prospective randomized studies they are sequential studies performed by the same cooperative group and the same investigators under similar study conditions.
While the data for younger adults appear clear-cut, the data for older adults, even for 45 mg/m 2 of daunorubicin, are equivocal and do not confirm the superiority of any anthracycline. 4, 5, 12 A recently completed ECOG trial prospectively compared three induction regimens -daunorubicin 45 mg/m 2 vs idarubicin 12 mg/m 2 vs mitoxantrone 12 mg/m 2 -all given intravenously for 3 days, together with an identical dose of cytarabine, 100 mg/m 2 for 7 days, as well as an identical consolidation regimen. In this trial there were no differences in the toxicity or efficacy observed among the three anthracyclines. 12 In the area of post-remission therapy the field is even more open and there are lots of uncertainties, or even misconceptions.
There are many regimens and options for post-remission therapy although there is a feeling expressed in certain publications that high-dose cytarabine is a critical element for the success of post-remission therapy. However, while the data confirm its effectiveness as post-remission therapy, it is doubtful that we need to subscribe to a dogma that it is critical and one cannot do the same with other regimens.
A recent publication, based on CALGB data, almost suggested that it would be unethical not to administer three to four cycles of high-dose cytarabine to patients with the t(8;21) abnormality 13 in which the disease-free survival was about 60%. However, the largest published trial of post-remission therapy in AML, conducted by the Medical Research Council in Britain 14 reported an identical disease-free survival in a much larger cohort of patients, without using high-dose cytarabine.
Furthermore, it is unknown how many cycles of high-dose cytarabine are necessary as the data on this are scanty and it is perhaps incredible how little thinking goes into giving someone four courses rather than two or three courses of highdose cytarabine with no data whatsoever that this makes a difference. Similarly, the optimal dose of high-dose cytarabine -anywhere from 1.5 g/m 2 to 3 g/m 2 , the optimal duration and the total number of doses have not been established.
Historically, secondary leukemias referred to patients with AML who have a history of prior environmental, occupational or therapeutic exposure to hematotoxins or radiation. Operationally, the term secondary leukemia includes any AML with distinct cytogenetic and molecular features. Thus, sec-ondary leukemias are better defined by cytogenetic and molecular characteristics, rather than patient history, as it is these features that determine the generally poor prognosis of these leukemias. Thus, patients with therapy-related AML who have a more favorable karyotype, such as inv(16), t(8;21) or t(15;17), have a similar prognosis to patients with de novo AML who present with these balanced translocations. 15 These secondary leukemias provide another example as to the vast uncertainty that exists in the therapy of such disorders. Because of the generally poor prognosis of these leukemias multiple publications have advocated alternative regimens implying that it would be almost unethical to give standard induction therapy. [16] [17] [18] However, there are no data that any form of therapy provides a better outcome than standard induction therapy consisting of an anthracycline and cytarabine. While an increasing number of patients with secondary leukemias have been treated, due to the increasing age for which patients with AML are now been reported, there is a remarkable paucity of data and virtually no prospective controlled trials for the therapy of these disorders. There is a great reluctance among treating physicians to enter such patients on standard protocols for AML. While there may be an intuitive advantage to employing biologic modifiers such as, for example, multidrug resistance (MDR1) modulators in these disorders, the ultimate best myeloablative regimen has not been determined and there has been no suggestion that one form of induction is better that another. In fact, if any regimen is found to be superior for secondary leukemias it will probably also be superior for those patients with AML who have more favorable prognostic features.
Over the past decade major attempts have been made to determine the role of bone marrow transplantation as consolidation therapy for AML patients in first remission. 14, [19] [20] [21] These have all been prospective randomized studies and each of the authors has expressed different opinions as to the appropriate conclusions to be drawn from these studies. However, it is fair to say that instead of having laid to rest any controversies regarding the role of autologous stem cell transplantation for first remission AML, the controversy and the issues linger. There is, however, a fundamental flaw in even trying to interpret many of these data and drawing conclusions. When these studies were designed, over a decade ago, it was thought that we had a simple and clear question to answer. Is an autologous transplant or chemotherapy better for AML patients in first complete remission. Subsequently, it became clear that such an answer would not suffice. A general answer for patients with AML was not relevant; we needed answers regarding the specific prognostic subgroups, generally divided into favorable, intermediate and unfavorable cytogenetics. When performing retrospective subgroup analyses the numbers were too small to allow us to make meaningful conclusions. Taking into account the typical high drop-out rate of patients who enter such transplant studies and ultimately receive their randomized therapy, and attempting to have enough patients to provide statistically meaningful data for each of the prognostic subgroups would require somewhere in the order of 7000 patients. Since such a mammoth study is unlikely to ever be conducted we are unlikely to ever get the correct answers. This however did not prevent major conclusions to be written and to have wide acceptance. An important example may be the value of using high-dose cytarabine as post-remission therapy. The initial abstract presentation in 1994 was very widely accepted based on a subgroup of only 18 patients with favorable cytogenetics. 22 In contrast, the US intergroup trial 20 demonstrated the exact opposite for this particular cytogenetic group and made a strong case for performing an autologous transplantation for such patients rather than using high-dose cytarabine. The answer must be obvious; the cohorts of patients in each of these studies were too small -which therefore should not surprise anyone when such contradictory findings are reported. The entire issue of bone marrow transplantation for AML in first complete remission remains unresolved despite prevailing opinions. While autologous transplantation seems to provide the most superior antileukemic activity, the ultimate benefit of this was negated by a very high rate of mortality in the major studies, reaching as high as 18% among adults in the largest published such study 14 and 14% in the US intergroup study. 20 It is important to remember that all of these studies used bone marrow as the source of the stem cells. With the advent of peripheral blood as the source of stem cells, and the resultant very low morbidity and mortality, it is unknown whether any of these major studies have relevance to presentday practice.
Thus, many questions remain wide open in the therapy of patients with AML. The information from induction therapy in AML demonstrates an important aspect. When strong views are held, these may be sustained even in the face of wellconducted randomized studies. The wide leeway given to the practice of post-remission therapy suggests an extraordinary bias in the way we chose to expend our energies on controversies in AML. Consider the intensity of the discussions regarding the use of cytokines in AML -a relatively marginal issue for a supportive care measure -compared with any lack of critical challenge when one admits a patient, off study for, say, a fourth cycle of post-remission therapy which is highly toxic, with no evidence for its efficacy and surely no evidence for cost-effectiveness.
The issue of stem cell transplantation as post-remission therapy will probably never be resolved as long as emotions run so high. It is reminiscent of the issue of stem cell purging a decade ago. Even some of its greatest proponents at the time referred to this as a religion. Clearly, we need to keep a critical eye, unhindered by prevailing biases, and allow ourselves to freely alter our established practice in the face of emerging data.
